Spain's Grifols buys Talecris for $4 billion

Related Topics

Quotes

   

MADRID | Mon Jun 7, 2010 6:51am BST

MADRID (Reuters) - Spanish healthcare company Grifols (GRLS.MC) has acquired Talecris Biotherapuetics TLCR.O, which produces plasma-based protein therapies, for $4 billion including debt.

Grifols estimates about $230 million annual synergies from the deal, which has been unanimously approved by both companies' boards and recommended to their shareholders, the Spanish company said in a statement on Monday.

On Sunday, sources had told Reuters the deal was likely to be in cash and stock.

(Reporting by Tracy Rucinski; Editing by Paul Day)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.